Compounds > n(delta)-(n-methyl-n-nitrosocarbamoyl)-l-ornithine
Page last updated: 2024-09-02

n(delta)-(n-methyl-n-nitrosocarbamoyl)-l-ornithine and ER-Negative PR-Negative HER2-Negative Breast Cancer

n(delta)-(n-methyl-n-nitrosocarbamoyl)-l-ornithine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, G; Huang, J; Li, B; Li, T; Lin, M; Shuai, X; Xiao, Z; Zhong, H1

Other Studies

1 other study(ies) available for n(delta)-(n-methyl-n-nitrosocarbamoyl)-l-ornithine and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Nanodrug Augmenting Antitumor Immunity for Enhanced TNBC Therapy via Pyroptosis and cGAS-STING Activation.
    Nano letters, 2023, 06-14, Volume: 23, Issue:11

    Topics: Animals; Cell Line, Tumor; Female; Hydrogen Peroxide; Mice; Nanoparticles; Nucleotidyltransferases; Pyroptosis; Triple Negative Breast Neoplasms

2023